New-onset bullous pemphigoid following the fifth dose of the COVID-19 vaccine Pfizer-BioNTech: A case report
Bullous pemphigoid is recognized as the most prevalent autoimmune blistering skin disease. This report presents a case of a 54-year-old male in Canada who developed new-onset bullous pemphigoid 4 weeks after receiving his fifth COVID-19 vaccine booster (Pfizer-BioNTech). The patient initially presen...
Saved in:
Main Author: | Eman Badawod |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2025-07-01
|
Series: | SAGE Open Medical Case Reports |
Online Access: | https://doi.org/10.1177/2050313X251357053 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bullous pemphigoid of Lever against the background of combined somatic pathology
by: E. N. Efanova, et al.
Published: (2021-06-01) -
A single dose of the Biontech/Pfizer BNT162b2 vaccine protected elderly residents from severe COVID‐19 during a SARS‐coronavirus‐2 outbreak in a senior citizen home in Germany
by: Rolf Schwarzer, et al.
Published: (2021-12-01) -
Evaluation of a novel chemiluminescent immunoassay for autoantibody detection in pemphigus and bullous pemphigoid
by: Na Zhang, et al.
Published: (2025-06-01) -
Correction: Evaluation of a novel chemiluminescent immunoassay for autoantibody detection in pemphigus and bullous pemphigoid
by: Na Zhang, et al.
Published: (2025-07-01) -
Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study
by: Lingyu Hu, et al.
Published: (2023-07-01)